237 related articles for article (PubMed ID: 28464832)
1. The E2F4 prognostic signature predicts pathological response to neoadjuvant chemotherapy in breast cancer patients.
Mark KMK; Varn FS; Ung MH; Qian F; Cheng C
BMC Cancer; 2017 May; 17(1):306. PubMed ID: 28464832
[TBL] [Abstract][Full Text] [Related]
2. E2F4 regulatory program predicts patient survival prognosis in breast cancer.
Khaleel SS; Andrews EH; Ung M; DiRenzo J; Cheng C
Breast Cancer Res; 2014 Dec; 16(6):486. PubMed ID: 25440089
[TBL] [Abstract][Full Text] [Related]
3. A framework to predict the applicability of Oncotype DX, MammaPrint, and E2F4 gene signatures for improving breast cancer prognostic prediction.
Yao K; Tong CY; Cheng C
Sci Rep; 2022 Feb; 12(1):2211. PubMed ID: 35140308
[TBL] [Abstract][Full Text] [Related]
4. Gene signature-based prediction of triple-negative breast cancer patient response to Neoadjuvant chemotherapy.
Zhao Y; Schaafsma E; Cheng C
Cancer Med; 2020 Sep; 9(17):6281-6295. PubMed ID: 32692484
[TBL] [Abstract][Full Text] [Related]
5. ER
Guerrero-Zotano AL; Stricker TP; Formisano L; Hutchinson KE; Stover DG; Lee KM; Schwarz LJ; Giltnane JM; Estrada MV; Jansen VM; Servetto A; Gavilá J; Perez-Fidalgo JA; Lluch A; Llombart-Cussac A; Bayar MA; Michiels S; André F; Arnedos M; Guillem V; Ruiz-Simon A; Arteaga CL
Clin Cancer Res; 2018 Jun; 24(11):2517-2529. PubMed ID: 29581135
[No Abstract] [Full Text] [Related]
6. Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value.
Lehmann BD; Ding Y; Viox DJ; Jiang M; Zheng Y; Liao W; Chen X; Xiang W; Yi Y
BMC Cancer; 2015 Mar; 15():179. PubMed ID: 25886164
[TBL] [Abstract][Full Text] [Related]
7. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
[TBL] [Abstract][Full Text] [Related]
8. On-treatment biomarkers can improve prediction of response to neoadjuvant chemotherapy in breast cancer.
Bownes RJ; Turnbull AK; Martinez-Perez C; Cameron DA; Sims AH; Oikonomidou O
Breast Cancer Res; 2019 Jun; 21(1):73. PubMed ID: 31200764
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer.
Yoshioka T; Hosoda M; Yamamoto M; Taguchi K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
Breast Cancer; 2015 Mar; 22(2):185-91. PubMed ID: 23645542
[TBL] [Abstract][Full Text] [Related]
10. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
[TBL] [Abstract][Full Text] [Related]
11. Multi-Gene Prognostic Signatures and Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in ER-positive, HER2-negative Breast Cancer Patients.
Mazo C; Barron S; Mooney C; Gallagher WM
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32369904
[TBL] [Abstract][Full Text] [Related]
12. An Immune-Associated Genomic Signature Effectively Predicts Pathologic Complete Response to Neoadjuvant Paclitaxel and Anthracycline-Based Chemotherapy in Breast Cancer.
Fu C; Liu Y; Han X; Pan Y; Wang HQ; Wang H; Dai H; Yang W
Front Immunol; 2021; 12():704655. PubMed ID: 34526986
[TBL] [Abstract][Full Text] [Related]
13. Relative Prognostic and Predictive Value of Gene Signature and Histologic Grade in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
Iwamoto T; Kelly C; Mizoo T; Nogami T; Motoki T; Shien T; Taira N; Hayashi N; Niikura N; Fujiwara T; Doihara H; Matsuoka J
Clin Breast Cancer; 2016 Apr; 16(2):95-100.e1. PubMed ID: 26631838
[TBL] [Abstract][Full Text] [Related]
14. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer.
Straver ME; Glas AM; Hannemann J; Wesseling J; van de Vijver MJ; Rutgers EJ; Vrancken Peeters MJ; van Tinteren H; Van't Veer LJ; Rodenhuis S
Breast Cancer Res Treat; 2010 Feb; 119(3):551-8. PubMed ID: 19214742
[TBL] [Abstract][Full Text] [Related]
15. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer.
Kawase M; Toyama T; Takahashi S; Sato S; Yoshimoto N; Endo Y; Asano T; Kobayashi S; Fujii Y; Yamashita H
Breast Cancer; 2015 May; 22(3):308-16. PubMed ID: 23771556
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of pretherapeutic Ki67 as a predictive parameter for response to neoadjuvant chemotherapy in breast cancer: is it equally useful across tumor subtypes?
Sueta A; Yamamoto Y; Hayashi M; Yamamoto S; Inao T; Ibusuki M; Murakami K; Iwase H
Surgery; 2014 May; 155(5):927-35. PubMed ID: 24582496
[TBL] [Abstract][Full Text] [Related]
17. Prognostic breast cancer signature identified from 3D culture model accurately predicts clinical outcome across independent datasets.
Martin KJ; Patrick DR; Bissell MJ; Fournier MV
PLoS One; 2008 Aug; 3(8):e2994. PubMed ID: 18714348
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant chemotherapy in ER+ HER2- breast cancer: response prediction based on immunohistochemical and molecular characteristics.
Lips EH; Mulder L; de Ronde JJ; Mandjes IA; Vincent A; Vrancken Peeters MT; Nederlof PM; Wesseling J; Rodenhuis S
Breast Cancer Res Treat; 2012 Feb; 131(3):827-36. PubMed ID: 21472434
[TBL] [Abstract][Full Text] [Related]
19. EndoPredict predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer.
Bertucci F; Finetti P; Viens P; Birnbaum D
Cancer Lett; 2014 Dec; 355(1):70-5. PubMed ID: 25218596
[TBL] [Abstract][Full Text] [Related]
20. Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy.
Ács B; Zámbó V; Vízkeleti L; Szász AM; Madaras L; Szentmártoni G; Tőkés T; Molnár BÁ; Molnár IA; Vári-Kakas S; Kulka J; Tőkés AM
Diagn Pathol; 2017 Feb; 12(1):20. PubMed ID: 28222768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
